Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LeMaitre eyes US market with UniFit abdominal stent graft trial:

This article was originally published in Clinica

Executive Summary

Moving its single-body aorto-uni-iliac stent graft closer to the US market, LeMaitre Vascular has begun a pivotal FDA-approved clinical trial of the product. The study - UNITE - will evaluate the safety and effectiveness of the company's UniFit abdominal stent graft in the treatment of aorto, aorto-iliac, and/or iliac aneurysms. It is expected to enrol 90 patients in up to 14 centres. Patients will be followed-up for at least one year, after which the Burlington, Massachusetts firm hopes to file a premarket approval application (PMA) for permission to sell the device in the US. UniFit is currently sold in Europe and in a small number of other countries.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel